Lantern Pharma Inc. (LTRN)
| Market Cap | 25.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.12M |
| Shares Out | 11.21M |
| EPS (ttm) | -1.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 286,231 |
| Open | 2.390 |
| Previous Close | 2.460 |
| Day's Range | 2.170 - 2.390 |
| 52-Week Range | 1.110 - 5.744 |
| Beta | 1.75 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About LTRN
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, in... [Read more]
Financial Performance
Financial StatementsNews
Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut.
Emerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA)...
Lantern Pharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators
Lantern leverages a proprietary AI platform to accelerate cancer drug development, with three clinical-stage drugs and a new subsidiary targeting neuro-oncology. The platform is now accessible to external researchers, opening significant market opportunities and generating revenue, while multiple FDA designations and upcoming data releases highlight strong clinical momentum.
Lantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN) (“Lantern” or the “Company”), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai — the world's first a...
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
DALLAS--(BUSINESS WIRE)--withZeta.ai is redefining how rare cancer research, discovery, drug development, and clinical trial design gets done.
Lantern Pharma Earnings Call Transcript: Q4 2025
Clinical programs advanced with strong trial results and multiple FDA designations, while AI platforms expanded commercially. Operating expenses fell 19% year-over-year, but additional funding is needed as cash runway extends only to late Q3 2026.
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates.
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
DALLAS--(BUSINESS WIRE)--Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report.
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
DALLAS--(BUSINESS WIRE)--Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001.
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET.
Lantern Pharma Transcript: AI Investor Conference: From Data Centers to Breakthrough Use Cases
AI-driven platforms have accelerated oncology drug development, reducing timelines and costs while enabling precision targeting and multiple FDA designations. Key catalysts include upcoming data for LP-300 and LP-184, the launch of Starlight Therapeutics, and the commercialization of withZeta.ai.
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026.
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discove...
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies
DALLAS--(BUSINESS WIRE)--A.I. center of excellence - Lantern Pharma.
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
DALLAS--(BUSINESS WIRE)--LP-184 Clinical Insights, KOL Webinar & Future Plans.
Lantern Pharma Transcript: Status Update
LP-184 demonstrated a favorable safety profile and durable disease control in heavily pretreated patients with advanced solid tumors, particularly those with DNA repair deficiencies and high PTGR1 expression. The drug shows strong preclinical and clinical efficacy, synergizes with PARP inhibitors, and is advancing to further trials with fast-track and orphan designations.
Lantern Pharma Earnings Call Transcript: Q3 2025
Q3 2025 marked a pivotal quarter with strong clinical progress, notably a 48% benefit rate in LP-184's phase I-A trial, and commercial advances in AI platforms. Net loss narrowed to $4.2M, with $12.4M in cash providing runway into Q3 2026.
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
DALLAS--(BUSINESS WIRE)--Q3 Press Release - BTM.
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET.
Lantern Pharma Transcript: 2025 ThinkEquity Conference
Five monetization opportunities were outlined, including three clinical-stage drugs, an open-access AI platform, and a neuro-oncology spinout. Lead assets target high-value cancer indications, with multiple fast track and orphan designations, and the company is launching new AI tools for rare cancer drug development.
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT.
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
DALLAS--(BUSINESS WIRE)--LP-284 at 25th LL&M Congress & CMR.
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025.
Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
DALLAS--(BUSINESS WIRE)--Clinical Trial Results, LP-184.
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)
AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce t...